APEX Biologix

Private

Woods Cross, UtahHealthcare & Life Scienceshttps://apexbiologix.com/

Last Round

Debt

Apr 10, 2026

Company Overview

APEX Biologix is a medical device company that designs and manufactures regenerative medicine products, including autologous biologic systems for platelet-rich plasma, bone marrow concentrate, and protein concentrate.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotech Equipment, Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

regenerative medicineplatelet-rich plasmaPRPbone marrow concentrateBMCmedical devicespoint-of-carebiologicsautologous cellscentrifugeorthopedic suppliesaesthetic medicineclinical trainingorthobiologicsstem cell therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

APEX Biologix Comps

Public and private peers based on sector, stage, and business model.

APEX Biologix comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

APEX Biologix Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Debt	Apr 10, 2026
Debt	Oct 14, 2025
Debt	Jul 15, 2025
Debt	Mar 24, 2025
Accelerator	Mar 28, 2022
Buyout/LBO	Apr 16, 2021

View all Funding Rounds

Key People

Founding team and executive leadership

Jim Rogers

Chief Executive Officer

Executive Team

APEX Biologix Investors

Notable investors and investment history

APEX Biologix investors
Investor	Rounds
RevTek Capital	Debt

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Nov 25, 2023
Grew 23% QoQ, from 30 to 37 employees.

View all signals

APEX Biologix Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

APEX Biologix Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about APEX Biologix's valuation, stock price, and market status.

Firmographic Details

HeadquartersWoods Cross, Utah

Employee Range66

Year Founded2014

Last FundingApr 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.